论文部分内容阅读
Cefixime是新的第三代口服头孢烯类抗生素。日本大阪大学医学院儿科和有关的28家儿科医院对Cefixime进行疗效和安全性评价。在251例可作疗效评价的病例中证明,Cefixime对上呼吸道感染的有效率为82.8%,对急性支气管炎为87.5%,对肺炎为72.1%,对溶血性链球菌性感染为100%,对尿路感染为93.3%,对耳鼻喉科感染为100%,总有效率为82.3%。三组给药剂量即每日10-12.9mg/kg、6.0-9.9mg/kg,3.0-5.9mg/kg的有效率各为86.8%、77.9%和82.7%。
Cefixime is the new third generation oral cephem antibiotic. Efficacy and safety evaluation of Cefixime in pediatrics of Osaka University Medical School and 28 pediatric hospitals in Japan. Among 251 curative evaluable cases, Cefixime showed an effective rate of upper respiratory tract infection of 82.8%, acute bronchitis 87.5%, pneumonia 72.1% and hemolytic streptococcal 100% Urinary tract infection was 93.3%, and ENT infection was 100%, with a total effective rate of 82.3%. The effective dose of the three groups administered at doses of 10-12.9 mg / kg, 6.0-9.9 mg / kg and 3.0-5.9 mg / kg per day were 86.8%, 77.9% and 82.7%, respectively.